| Cat. No. |
Product Name |
Information |
| PC-60074 |
Glumetinib
c-Met inhibitor
|
Glumetinib (SCC 244) is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM. |
| PC-45885 |
Crizotinib
c-Met inhibitor
|
Crizotinib (PF-02341066;PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with Ki of 4 nM. |
| PC-45842 |
Tivantinib
c-Met inhibitor
|
Tivantinib (ARQ-197) is a potent, selective, non-ATP-competitive inhibitor of c-Met with Ki of 355 nM. |
| PC-45841 |
JNJ-38877605
c-Met inhibitor
|
JNJ-38877605 is a potent, selective, ATP-competitive inhibitor of catalytic activity c-Met with IC50 of 4 nM. |
| PC-42535 |
Foretinib
c-Met inhibitor
|
Foretinib (XL880, GSK1363089, GSK089, EXEL-2880) is a potent, multikinase inhibitor that inhibits c-Met and VEGFR, also KIT, Flt-3, PDGFRβ, and Tie-2. |
| PC-45848 |
MK-2461
c-Met inhibitor
|
MK-2461 is a potent multitargeted kinase inhibitor that preferentially inhibits c-Met with IC50 of 2.5 nM, with similar potencies for Ron and Flt1 (IC50=7 and 10 nM, respectively). |
| PC-42618 |
BMS-794833
Met/VEGFR2 inhibitor
|
BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2 with IC50 of 1.7 nM/15 nM. |
| PC-45530 |
AMG-337
c-Met inhibitor
|
AMG-337 is a potent and selective inhibitor of MET with biochemical IC50 of 1 nM. |
| PC-21442 |
WM-S1-030
Ron kinase inhibitor
|
WM-S1-030 is a highly potent, specific inhibitor of recepteur d'origine nantais (RON kinase, MST1R) with IC50 of 0.39 nM in in vitro enzyme activity. |
| PC-49451 |
D6808
c-MET inhibitor
|
D6808 is a highly selective and potent macrocyclic c-Met inhibitor with IC50 of 2.9 nM. |
| PC-49280 |
c-MET inhibitor 7
c-MET inhibitor
|
c-MET inhibitor 7 is a potent, highly selective c-MET inhibitor with IC50 of 0.90 and 0.09 μM for wild-type and D1228V c-MET, respectively. |
| PC-38624 |
Altiratinib
MET/TIE-2/VEGFR inhibitor
|
Altiratinib (DCC-2701) is a potent c-MET/TIE-2/VEGFR inhibitor with IC50 of 2.7 nM (MET WT), 8.0 nM (TIE2 kinase) and 9.2 nM (VEGFR2), also potently inhibits oncogenic MET mutations in the switch region (residues 1228, 1230, and 1250) with IC50 range of 0.37-6 nM. |
